AIZ
71
-2
CME
56
-3
ORLY
64
2
TRIP
60
3
AEP
59
-3
M
14
2
SBUX
41
-3
MCD
63
-4
VRSK
35
-3
TXT
58
-2
HRL
38
2
ABBV
51
-2
IR
69
-2
ADT
33
5
GD
57
-2
CCI
36
-5
PX
52
-3
GE
85
3
VRSN
50
-5
ETN
73
-2
AIZ
71
-2
CME
56
-3
ORLY
64
2
TRIP
60
3
AEP
59
-3
M
14
2
SBUX
41
-3
MCD
63
-4
VRSK
35
-3
TXT
58
-2
HRL
38
2
ABBV
51
-2
IR
69
-2
ADT
33
5
GD
57
-2
CCI
36
-5
PX
52
-3
GE
85
3
VRSN
50
-5
ETN
73
-2
Financhill
Back

Oncternal Therapeutics Quote, Financials, Valuation and Earnings

The Next Tech Giant in Your Pocket?

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.
Sell
3

ONCT
Oncternal Therapeutics

Last Price:
1.70
Seasonality Move:
5.35%

7 Day Trial

ALL ACCESS PASS

$ 7

32,481% Growth? Meet Mode Mobile's "EarnPhone"

This is a paid advertisement for Mode Mobile Regulation A offering. Please read the offering circular and related risks at invest.modemobile.com.

Oncternal Therapeutics Price Quote

$1.70
+0.01 (+0.59%)
(Updated: September 19, 2024 at 3:50 PM ET)

Oncternal Therapeutics Key Stats

Sell
3
Oncternal Therapeutics (ONCT) is a Sell
Day range:
$1.48 - $1.80
52-week range:
$1.32 - $13.14
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
0.00
P/B ratio:
0.32%
Volume:
168.6K
Avg. volume:
57.6K
1-year change:
-74.69%
Market cap:
$5M
Revenue:
$0
EPS:
$-12.15

How Much Does Oncternal Therapeutics Make?

Data Unavailable

Is Oncternal Therapeutics Growing As A Company?

Data Unavailable

Oncternal Therapeutics Stock Price Performance

What Is Oncternal Therapeutics 52-Week High & Low?

Oncternal Therapeutics Price To Free Cash Flow

Data Unavailable

Is It Risky To Buy Oncternal Therapeutics?

Is Oncternal Therapeutics Cash Flow Positive?

  • What Is ONCT Cash Flow From Operations?
    Cash flow from operations (TTM) is -$25.2M
  • What Is Oncternal Therapeutics’s Cash Flow From Financing?
    Cash flow from financing (TTM) is -$137K
  • What Is Oncternal Therapeutics’s Cash Flow From Investing?
    Cash flow from investing (TTM) is $15.9M

Oncternal Therapeutics Return On Invested Capital

Data Unavailable

Oncternal Therapeutics Earnings Date & Stock Price

Oncternal Therapeutics Competitors

Oncternal Therapeutics Dividend Yield

Oncternal Therapeutics Analyst Estimates

YoY Growth Past Surprise
EPS: 0% 4.73%
Revenue: 0% 405.91%

Analyst Recommendations

Buy Recommendations: 0
Hold Recommendations: 2
Sell Recommendations: 0
Price Target: 10.00
Upside from Last Price: 491.72%

Major Shareholders

  • How many ONCT shares are owned by institutional investors?
    770.6K ONCT shares are owned by institutional investors
  • How many ONCT shares are owned by insiders?
    0 ONCT shares are owned by insiders